li001

Clinic Study Identifies P2RX7 as Key Driver of Immunotherapy Resistance in Lung Cancer

Research Advances /

Researchers at have discovered how lung tumors can manipulate the immune system to protect themselves. The study, published in Cancer Immunology Research, helps explain why many patients with non-small cell lung cancer (NSCLC) do not respond well to immunotherapy and points to a possible new treatment target. The research focuses on regulatory T cells, or […]

Clinic Study Identifies P2RX7 as Key Driver of Immunotherapy Resistance in Lung Cancer Read More »

Pancreatic Cancer Frontline Treatment Expands to Three Options in 2026

Treatment /

In 2026, first-line treatment for metastatic pancreatic cancer has expanded from two main options to three. Doctors must choose carefully because there is still no perfect biomarker to guide decisions. The approval of NALIRIFOX in February 2024, based on the NAPOLI 3 trial, added a new standard to existing treatments. The three main frontline regimens

Pancreatic Cancer Frontline Treatment Expands to Three Options in 2026 Read More »

Clinical Trial Shows 100% Response for Fixed-Duration CLL Therapy

Treatment /

A Phase 2 trial shows that a fixed-duration combination of obinutuzumab and venetoclax is highly effective for untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL). All patients responded to treatment, with 90% achieving complete or near-complete remission and 100% reaching undetectable levels of residual disease by the ninth cycle. Three months after treatment,

Clinical Trial Shows 100% Response for Fixed-Duration CLL Therapy Read More »

EU Approves Anktiva Plus BCG for Hard-to-Treat Bladder Cancer

Drug Approvals /

The European Commission has granted conditional marketing approval to Anktiva in combination with BCG for adults with high-grade, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Until now, patients in Europe whose cancer did not respond to BCG often had very limited options and frequently needed radical cystectomy, the surgical removal of the bladder. The decision is

EU Approves Anktiva Plus BCG for Hard-to-Treat Bladder Cancer Read More »

Study Finds Vaccine Structure Dramatically Boosts Cancer-Fighting Immune Response

Research Advances /

Researchers have shown that in cancer vaccines, how the ingredients are arranged can be just as important as what they are made of. A new study demonstrates structural nanomedicine, a field focused on nanoscale vaccine design. Scientists discovered that simply changing how a cancer-targeting peptide is positioned on a nanoparticle can greatly strengthen the immune

Study Finds Vaccine Structure Dramatically Boosts Cancer-Fighting Immune Response Read More »

Matrix Stiffness Drives Pancreatic Cancer Growth and Chemotherapy Resistance via DCLK1 Pathway

Molecular Oncology /

Pancreatic ductal adenocarcinoma (PDAC) tumors are extremely stiff, and new research shows that this stiffness directly drives tumor growth and chemotherapy resistance. Clinical data from 63 patients using EUS elastography revealed that stiffer tumors (high strain ratio) are associated with advanced tumor stage, more lymph node involvement, and higher rates of metastasis. The study identified

Matrix Stiffness Drives Pancreatic Cancer Growth and Chemotherapy Resistance via DCLK1 Pathway Read More »

Liquid Biopsy Using cfDNA Methylation Shows Promise for Early Detection and Monitoring of Ovarian Cancer

Diagnostics /

Ovarian cancer is one of the deadliest gynecological cancers, partly because early detection is difficult. Traditional blood markers like CA125 and HE4 often miss early-stage disease, and tissue biopsies cannot capture the full complexity of tumors. cfDNA methylation liquid biopsy is emerging as a non-invasive and highly sensitive alternative for diagnosis, prognosis, and monitoring treatment.

Liquid Biopsy Using cfDNA Methylation Shows Promise for Early Detection and Monitoring of Ovarian Cancer Read More »

FES-PET/CT Offers Superior Detection and Hormone Therapy Guidance for Lobular Breast Cancer

Technology Innovation /

Traditional imaging often misses lobular breast cancer because these cells do not form solid tumors and float freely, making them hard to detect with scans that rely on tumor size or glucose metabolism. FES-PET/CT offers a better alternative by targeting estrogen receptors (ER), which lobular cancer cells depend on. Compared with standard FDG-PET/CT, which uses

FES-PET/CT Offers Superior Detection and Hormone Therapy Guidance for Lobular Breast Cancer Read More »

New Study Shows Zanubrutinib Improves PFS Over Other BTK Inhibitors in R/R CLL

Treatment /

A recent study suggests that Brukinsa (zanubrutinib) provides better progression-free survival than other BTK inhibitors in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The study compared zanubrutinib with Calquence (acalabrutinib) and Imbruvica (ibrutinib) by adjusting data from three major Phase 3 trials—ALPINE, ELEVATE-RR, and ASCEND—to make fair comparisons. The results showed that zanubrutinib reduced

New Study Shows Zanubrutinib Improves PFS Over Other BTK Inhibitors in R/R CLL Read More »

FDA Accepts Iberdomide NDA and Grants Breakthrough Designation for Relapsed/Refractory Multiple Myeloma

Drug Approvals /

The U.S. Food and Drug Administration has accepted a New Drug Application for iberdomide, an oral CELMoD, to be used with Darzalex (daratumumab) and dexamethasone for patients with relapsed or refractory multiple myeloma. The combination, known as IberDd, has received Breakthrough Therapy Designation. The application is based on interim results from the Phase 3 EXCALIBER-RRMM

FDA Accepts Iberdomide NDA and Grants Breakthrough Designation for Relapsed/Refractory Multiple Myeloma Read More »